Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

274.01 +3.76 (+1.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Biogen Unusual Options Activity
 
Via Benzinga
11 Analysts Have This to Say About Biogen
 
Via Benzinga
7 Blue-Chip Stocks Sitting in the Sweet Spot
Although blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move. 
Via InvestorPlace
Elliott Wave Technical Analysis: Biogen Inc. - Thursday, March 23
Looking for longs after a clear resumption of the uptrend. 
Via Talk Markets
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
The companies are focusing on a small population of ALS patients with a genetic mutation. 
Via Investor's Business Daily
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder
 
Via Benzinga
iMetabolic BioPharma's Alzheimer's Disease Therapeutic Innovation Is A Breakthrough Three-Pronged Approach
Interested in investing in iMetabolic BioPharma? Click here to get started! 
Via Benzinga
Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit
 
Via Benzinga
Should You Buy Biogen Before a Big July Decision?
Biogen stock has dropped about 40% from its record high. 
Via The Motley Fool
Price Over Earnings Overview: Biogen
 
Via Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023. 
Via InvestorPlace
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. 
Via Benzinga
(BIIB) - Analyzing Biogen's Short Interest
 
Via Benzinga
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
 
Via Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
 
Via Benzinga
Biogen's Debt Overview
 
Via Benzinga
1 Reason to Buy Biogen Stock, and 1 Reason to Sell
It could be a make or break year for the biotech. 
Via The Motley Fool
Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approval
The FDA approved Reata's Friedreich's ataxia treatment, Skyclarys. 
Via Investor's Business Daily
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
 
Via Benzinga
Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone
 
Via Benzinga
Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed
The company is definitively closing the door on solanezumab. 
Via Investor's Business Daily
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
Any Alzheimer's drug that worked would be an instant blockbuster, but science doesn't work on an investor's schedule. 
Via InvestorPlace
Elliott Wave Technical Analysis: Biogen Inc. - Wednesday, March 8
Looking for a bottom in wave {v} to then look for longs. 
Via Talk Markets
Why Shares of Anavex Life Sciences Rose 12.4% in February
The company's first-quarter earnings report detailed positive news regarding its pipeline. 
Via The Motley Fool
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
 
Via Benzinga
What Does Biogen's Debt Look Like?
Shares of Biogen Inc. (NASDAQ:BIIB) moved lower by 7.52% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its... 
Via Benzinga
Peering Into Biogen's Recent Short Interest
Biogen's (NASDAQ:BIIB) short percent of float has fallen 8.84% since its last report. The company recently reported that it has 1.71 million shares sold short, which is 1.34% of all regular shares that... 
Via Benzinga
Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit
The FDA is set to review the company's neurological drug by Tuesday. 
Via Investor's Business Daily
Why Reata Pharmaceuticals Shares Are Falling Monday?
According to various reports, the FDA's neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately. 
Via Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.